

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
                                  )  
                                  )  
Hans-Arne HANSSON et al. ) Group Art Unit: 1649  
                                  )  
                                  )  
Application No.: 10/573,601 ) Examiner: Aditi Dutt  
                                  )  
                                  )  
Filed: August 11, 2006       ) Confirmation No.: 6872  
                                  )  
                                  )  
For: NOVEL USE OF ANTISECRETORY )  
    FACTOR                     )  
                                  )

**RESPONSE TO RESTRICTION AND ELECTION OF SPECIES REQUIREMENTS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Restriction and Election of Species Requirements dated May 5, 2008, Applicants submit the following Response.

The Office has required that the present application be restricted to one of the following six (6) groups of claims:

- Group I:       Claims 3-5, drawn to a method of treating and/or preventing a condition associated with loss or gain of nervous tissue administering an antisecretory protein inducing food;
- Group II:       Claim 16, drawn to a method of inducing the formation of an antisecretory protein comprising administering a food of a solution made from malted cereal;
- Group III:       Claims 20-22, 36, and 37, drawn to a method of propagating, inducing and/or maintaining the genesis of an isolated stem cell progeny in vitro, by treating the isolated cell with an antisecretory protein, or an oligo or polypeptide derivatives thereof, comprising Formula I;
- Group IV:       Claims 23-35, 41, and 42, drawn to a method of treatment or prevention of a condition associated with a gain or loss of nervous tissue, comprising administering an effective amount of an antisecretory protein or an oligopeptide thereof, comprising Formula I;
- Group V:       Claims 38 and 40, drawn to a method of propagating, inducing and/or maintaining the genesis of an isolated stem cell progeny from a germinal layer from a patient, administering an effective amount of an